FAM160A2功能缺失性突变可能诱发心房颤动

心房颤动(atrial fibrillation, AF)是临床最常见的心律失常,对AF致病基因的研究,有助于AF早期筛查。本文旨在家族性AF人群和散发性AF人群中筛选具有潜在发病意义的易感基因,并对其在AF发生机制进行初步探讨。首先对4名家族性AF进行全外显子组测序(WES),鉴定AF相关基因。然后用Sanger测序在非家族性AF人群和健康人群中证实易感基因突变情况,应用Western印迹分析其蛋白质表达情况,利用膜片钳技术分析突变基因对外向钾离子电流的影响。家族共有39人,其中有4人发生AF,这4名AF患者存在2个共有的突变基因FAM160A2(纯合突变,rs77726581 c.1375C>T)和MUC5B(杂合突变,rs199736618 c.12272C>T)。在52例非家族性AF患者中,有5例存在FAM160A2相同位点杂合突变,在健康人群中未发现此突变;而MUC5B在非家族性AF人群和健康人群中均发生杂合突变。FAM160A2蛋白在非家族性AF散发人群和健康人群中表达水平并无显著性差异。FAM160A2基因突变明显降低外向钾离子电流(与野生型比较,P<0...     

4.1B蛋白的抑制肿瘤作用

4.1 R和Merlin是4.1蛋白超家族中两个功能比较清楚的成员,前者通过结合肌动蛋白和血影蛋白维持红细胞骨架结构的完整性:后者为抑癌蛋白,其缺失与脑膜瘤发生有关.4.1B蛋白是4.1R和Merlin的同源蛋白,与二者的结构和功能具有相似性.4.1B蛋白由三个保守的结构域构成,即FERM、SABD和CTD,通过这三个结构域,能与一系列蛋白质相互作用.4.1 B蛋白表达缺失与脑膜瘤、乳腺癌和非小细胞肺癌的发生相关,而过量表达则可激活JNK信号途径,促进细胞凋亡;此外,4.1 B蛋白还具有抑制肿瘤转移的功能.因此,目前多认为4.1B基因可能是一个抑癌基因.     

癌基因和抑癌基因研究进展

癌基因和抑癌基因的发现和研究是肿瘤研究史上的一个里程碑,标志着肿瘤研究进入了分子时代,从而在更深层次上为阐明基因的结构、表达、调控、功能的改变与肿瘤形成的关系提供了科学依据和可能性,具有重要的理论和实际意义。本文概述了癌基因和抑癌基因的最新研究进展。     

人FAM33A基因启动子的克隆与鉴定

目的鉴定人FAM33A基因的启动子,为进一步研究其转录调控机制奠定基础。方法采用5’RACE技术（5’端cDNA快速扩增）鉴定FAM33A的转录起始位点。采用PCR定向克隆、酶切亚克隆等策略,构建FAM33A启动子荧光素酶报告基因。采用Lipofeetamine^TM2000转染H1299细胞,并通过Dual-Lu-ciferase@ Reporter Assay System进行荧光素酶报告基因活性检测。结果确定了FAM33A的转录起始位点,构建了覆盖FAM33A 5’端ATG附近约2kb区域的一系列FAM33A启动子荧光素酶报告基因。启动子活性分析表明,这些重组体均具有较高的启动子活性,同时含有典型的GC盒以及Sp1、E2F和GATA-1等潜在的转录因子结合位点。结论FAM33A启动子区域主要定位于转录起始位点附近约590bp的区域内。     

Ska2/FAM33A:一个参与细胞周期调控与肿瘤发生的新基因

Ska2(spindle and KT associated 2),也称FAM33A(family with sequence similarity 33,member A),是一个最近鉴定的参与细胞周期调控与肿瘤发生发展的新基因。现有研究初步证实,Ska2参与组成Ska复合体,在有丝分裂中期纺锤体检验点关闭中起重要作用;Ska2在小细胞肺癌和乳腺癌中呈现表达上调,可通过糖皮质激素受体等途径参与细胞增殖调节和肿瘤发生发展;NF-κΒ和CREB等转录因子可能参与Ska2的表达调控。Ska2有望成为一个恶性肿瘤诊断和靶向治疗的新靶点。     

心脏特异表达人源FAM55A转基因小鼠的建立

目的建立心脏特异表达的人源FAM55A转基因小鼠,为研究该基因在心肌病发病中的作用提供模型。方法 Western blot检测FAM55A在野生型小鼠与cTnTR141W转基因小鼠心脏组织中的表达变化及其在野生小鼠的组织表达谱。克隆人源FAM55A基因入α-MHC启动子下游构建a-MHC-FAM55A表达载体,显微注射法建立FAM55A转基因小鼠。PCR鉴定转基因首建鼠的基因型。Western blot鉴定人源FAM55A在转基因小鼠心脏中的表达,超声检测转基因小鼠心脏的几何构型和功能。HE染色检测转基因小鼠心脏的病理改变。结果 FAM55A在野生型小鼠心脏中有少量表达,在扩张型心肌病小鼠的心脏中表达增加。建立了1个心脏组织特异表达人源FAM55A转基因小鼠品系。与野生型小鼠相比,FAM55A转基因小鼠的心脏收缩期和舒张期左室前壁从1月龄到5月龄持续增厚,3月龄转基因小鼠心脏射血分数和短轴缩短率稍有增强,1月龄和5月龄转基因小鼠心脏功能则与同龄野生型小鼠相比无变化。组织学检测显示,转基因小鼠心脏左室心肌细胞不均匀肥大,但不发生紊乱。结论 FAM55A在扩张型心肌病小鼠的心脏中表达上调,建立了心脏特异表达的人源FAM55A转基因小鼠,为进一步和心肌病小鼠模型杂交,研究该基因在心肌病发病中的作用提供了工具。     

与肿瘤转移有关的基因的研究进展

与肿瘤转移有关的基因的研究进展姚旻,周信达（上海医科大学肝癌研究所,上海２０００３２）关键词癌基因,抑癌基因,肿瘤转移相关基因肿瘤转移过程复杂,包括①肿瘤细胞通过表面受体和细胞外基质发生特异性粘附;②肿瘤细胞本身或局部微生态系统（ｍｉｃｒｏｅｃｏｓｙ...     

抑癌基因ARID1A在肿瘤中的研究进展

染色质重塑复合物相关基因在癌症中频繁突变,这种现象逐渐引起研究者的重视。然而,染色质重塑活动如何引起癌症发生,对此机理研究甚少。ARID1A是SWl／SNF（BRG1相关因子）染色质重塑复合物中的一个亚基,具有DNA结合活性,可以与富含AT的DNA序列特异性结合。近来基因组测序发现,ARID1A在卵巢癌、肝癌、胃癌、乳腺癌等肿瘤中频繁发生突变,这些突变导致ARID1A在肿瘤中表达降低,表明ARID1A是个潜在的抑癌基因。该文将针对ARID1A在各种癌症中的缺失及失活机制、ARID1A的生物学功能和潜在抑癌机理以及与,临床预后之间关系等方面做一综述,以期为肿瘤诊断、治疗提供新思路。     

热休克蛋白gp96在恶性肿瘤中的研究进展

热休克蛋白90B1又称为糖蛋白96 (gp96). gp96属于热休克蛋白90家族,是一种高度保守且普遍存在的糖蛋白.作为一种内质网蛋白,gp96在维持内质网稳态、内质网应激、钙稳态等方面起着重要的调控作用,这些调控网络在肿瘤的发生发展过程中起着重要的作用. gp96作为分子伴侣在稳定和激活客户蛋白等方面有众多报道,其中包括HER2、整合素和Toll样受体等多个客户蛋白.大量研究表明,gp96在肝癌、乳腺癌、胃癌等不同类型的肿瘤中高表达,并在肿瘤的生长、侵袭和转移等方面起着重要的作用.本文从gp96的基本结构和功能及其在肿瘤发生发展中的作用等方面进行综述,并着重阐述细胞膜gp96相关的研究进展.最后,重点介绍基于胞膜gp96结构所设计的选择性小分子抑制剂、抗体和多肽等药物在肿瘤靶向治疗中的潜在应用.     

NGAL的结构与功能研究进展

NGAL（neutrophil gelatinase-associated lipocalin)是一种新的lipocalin,其结构与功能的研究进展为人瞩目,目前认为NGAL具有运输疏水性分子,调节明胶酶B（gelatinaseB或matrix metalloproteinase-9,MMP-9)活性等功能,并可能参与免疫炎症反应以及肿瘤的发生发展,特别是肿瘤的浸润转移等过程,最近,NGAL蛋白的空间结构已被研究清楚,这对于促进NGAL生物学作用或功能的研究。特别是对其新的生物学作用或功能的探索,比如与肿瘤的关系（NGAL可能是一种新的癌基因或促癌基因）将具有十分重要的意义。对此作者进行了综合评述。     

Identification of FAM96B as a novel prelamin A binding partner

Prelamin A accumulation causes nuclear abnormalities, impairs nuclear functions, and eventually promotes cellular senescence. However, the underlying mechanism of how prelamin A promotes cellular senescence is still poorly understood. Here we carried out a yeast two-hybrid screen using a human skeletal muscle cDNA library to search for prelamin A binding partners, and identified FAM96B as a prelamin A binding partner. The interaction of FAM96B with prelamin A was confirmed by GST pull-down and co-immunoprecipitation experiments. Furthermore, co-localization experiments by fluorescent confocal microscopy revealed that FAM96B colocalized with prelamin A in HEK-293 cells. Taken together, our data demonstrated the physical interaction between FAM96B and prelamin A, which may provide some clues to the mechanisms of prelamin A in premature aging.     

FAM98A associates with DDX1-C14orf166-FAM98B in a novel complex involved in colorectal cancer progression

Protein Arginine Methyl Transferase 1 (PRMT1) is deemed to be a potential oncogenic protein considering its overexpression in several malignancies including colorectal cancer. However, the molecular pathogenesis regarding PRMT1 overexpression and overall poor patient survival involved in this devastating and life threatening cancer remains obscured. In our previous study, we have identified FAM98A as a novel substrate of PRMT1 and also identified its role in ovarian cancer progression. Here, we showed that the two structural homologs FAM98A and FAM98B included in a novel complex with DDX1 and C14orf166 are required for PRMT1 expression. Analysis of the data from The Cancer Genome Atlas (TCGA) database and clinical colorectal cancer specimens also demonstrated a strong positive correlation and co-occurrence of PRMT1, FAM98A and FAM98B. These findings provide a mechanistic insight into how knockdown of FAM98A or FAM98B can suppress the malignant characteristics of cancer cells. Besides, we showed that FAM98A and FAM98B are working in the same axis as knockdown of both proteins together does not cause additional reduction in the cellular proliferation and colony formation of colorectal cancer cells.     

DNMT3B-mediated FAM111B methylation promotes papillary thyroid tumor glycolysis,growth and metastasis

Over the past decades, the incidence of thyroid cancer (TC) rapidly increased all over the world, with the papillary thyroid cancer (PTC) accounting for the vast majority of TC cases. It is crucial to investigate novel diagnostic and therapeutic targets for PTC and explore more detailed molecular mechanisms in the carcinogenesis and progression of PTC. Based on the TCGA and GEO databases, FAM111B is downregulated in PTC tissues and predicts better prognosis in PTC patients. FAM111B suppresses the growth, migration, invasion and glycolysis of PTC both in vitro and in vivo. Furthermore, estrogen inhibits FAM111B expression by DNMT3B methylation via enhancing the recruitment of DNMT3B to FAM111B promoter. DNMT3B-mediated FAM111B methylation accelerates the growth, migration, invasion and glycolysis of PTC cells. In clinical TC patient specimens, the expression of FAM111B is inversely correlated with the expressions of DNMT3B and the glycolytic gene PGK1. Besides, the expression of FAM111B is inversely correlated while DNMT3B is positively correlated with glucose uptake in PTC patients. Our work established E2/DNMT3B/FAM111B as a crucial axis in regulating the growth and progression of PTC. Suppression of DNMT3B or promotion of FAM111B will be potential promising strategies in the estrogen induced PTC.